| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 8 of 11 | 1 | Cision News | ||
| 01.10. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the eighth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 01.10. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update third quarter 2026 | 1 | Cision News | ||
| 27.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works brings forward the publication of its interim report for the third quarter of 2026 | 1 | Cision News | ||
| 25.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Secures New US Customer in the Development of Next-Generation Medicine | 2 | Cision News | ||
| 21.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports second quarter 2026 | 1 | Cision News | ||
| 18.08. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB appoints Eva Lindskog as new CEO | 1 | Cision News | ||
| 17.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 22,6 MSEK from Returning Customer | 2 | Cision News | ||
| 15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 7 of 11 | 1 | Cision News | ||
| 06.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for 8,9 MSEK from Returning Customer | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the seventh exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News | ||
| 01.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB - Business Update second quarter 2026 | 1 | Cision News | ||
| 04.06. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2026 | 1 | Cision News |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,430 | +10,26 % | Helix BioPharma Corp. reports Q3 results | ||
| DAMORA THERAPEUTICS | 22,980 | 0,00 % | Damora Therapeutics forciert CALR-Pipeline: Milliardenpotenzial bei Blutkrebs-Therapien im Fokus | ||
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 |